TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11422739
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion with AT1R blockade
Study: 9865645
Drug: Ciprofloxacin hydrochloride,
Normalized name: Ciprofloxacin Hydrochloride, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin hydrochloride, 400 mg every 12 hours, and metronidazole hydrochloride, 500 mg every 6 hours
Study: 9865645
Drug: Gentamicin sulfate,
Normalized name: Gentamicin Sulfate, Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin sulfate, 2.5 mg/kg every 12 hours, and metronidazole hydrochloride, 500 mg every 6 hours
Study: 7878282
Drug: Isosorbide-5-mononitrate (IS-5-MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 40 mg/12 hours
Study: 7878282
Drug: Isosorbide-5-mononitrate (IS-5-MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 40 mg/8 hours
Study: 25888180
Drug: Antibiotic checklist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic checklist implementation
Study: 22859496
Drug: 180 μg
Normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 μg PegIFN for 48 weeks
Study: 22859496
Drug: 180 μg
Normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks
Study: 22859496
Drug: 180 μg
Normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 μg PegIFN plus lamivudine for 48 weeks then 135 μg PegIFN for 48 weeks
Study: 20234035
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (2.25 g) plus policosanol (10 mg) for 21 days
Study: 17823447
Drug: Low-fat fermented
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat fermented milk enriched with 0.8 g plant sterol (PS) ester per portion, consumed daily for 6 weeks
Study: 17823447
Drug: Control low-fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control low-fat fermented milk, consumed daily for 6 weeks
Study: 11522565
Drug: High-fiber, high-fruit-and-vegetable,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber, high-fruit-and-vegetable, low-fat diet (4.30 g/MJ fiber, 0.84 servings/MJ fruit and vegetables, 20% of energy from fat)
Study: 9051389
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ALA daily for 4 months
Study: 8330461
Drug: Quinine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (oral doses)
Study: 8330461
Drug: Quinidine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (oral doses)
Study: 2451815
Drug: Flupirtine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (80 mg i.v.)
Study: 2451815
Drug: Pentazocine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (30 mg i.v.)
Study: 2551070
Drug: 75 XaI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 XaI U/kg b.w. twice daily Logiparin
Study: 2551070
Drug: 150 XaI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 XaI U/kg b.w. once daily Logiparin
Study: 2551070
Drug: Logiparin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Logiparin treatment
Study: 23677816
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention including medication review, education on osteoporosis, risk factors, lifestyle modifications, goals of therapy, side effects, and importance of medication adherence at months 0, 3, 6, and 12
Study: 19824379
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus ovestin (daily intravaginal administration for 2 weeks, then twice a week)
Study: 15208504
Drug: 99mTc‐L,L‐EC scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐L,L‐EC scan
Study: 11588692
Drug: Ramoplanin 100
Normalized name: RAMOPLANIN
DrugBank: Ramoplanin (DB04952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramoplanin 100 mg
Study: 11588692
Drug: Ramoplanin 400
Normalized name: RAMOPLANIN
DrugBank: Ramoplanin (DB04952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramoplanin 400 mg
Study: 9613276
Drug: Epidural blockade
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blockade with 0.9% saline (16 ml) prior to incision and 0.5% bupivacaine (15 ml) + fentanyl 50 micrograms (1 ml) prior to closure.
Study: 9613276
Drug: Epidural blockade
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blockade with 0.5% bupivacaine (15 ml) + fentanyl 50 micrograms (1 ml) prior to incision and 0.9% saline prior to closure.
Study: 27349220
Drug: Low-volume oral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume oral sulfate solution (OSS)
Study: 30400725
Drug: 4-L polyethylene
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-L polyethylene glycol (PEG)
Study: 26297239
Drug: Discharge medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge medication counselling and medication review by a clinical pharmacist
Study: 23947774
Drug: Structured communication
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured communication approach (DIALOG) with principles of solution-focused therapy, 6 meetings over 6 months
Study: 21324674
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) 4 mg intravenous every 3 months for 2 years (arm A)
Study: 17296236
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine administered into the tonsillar region
Study: 17296236
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml 0.9% saline administered into the tonsillar region
Study: 3141220
Drug: hFSH/hMG on
Approvals — FDA: no, EMA: no, PMDA: no
Description: hFSH/hMG on days 3 and 4 of the cycle followed by two ampules of hMG daily
Study: 3141220
Drug: Constant daily
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant daily dose of 2 ampules of hMG
Study: 26439234
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with Animal-Assisted Therapy (E+ATT; n = 8)
Study: 21723684
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume contrast media (0.5 ml/kg) and low kV (100) in group B
Study: 21723684
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume contrast media (1 ml/kg) and standard kV (120) in group A
Study: 19114966
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 IU) daily for five days during two menstrual cycles
Study: 19114966
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical in appearance to vitamin E) daily for five days during two menstrual cycles
Study: 15322504
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (dalteparin)
Study: 9509802
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate (6 mg/kg per day)
Study: 2646753
Drug: Piroxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (40 mg on days 1 and 2, additional 20 mg on day 3 if necessary)
Study: 2646753
Drug: Naproxen (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (1,000 mg on days 1 and 2, additional 500 mg on day 3 if necessary)
Study: 23543447
Drug: Adefovir (ADV)
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir (ADV) monotherapy
Study: 23543447
Drug: Lamivudine (LAM)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (LAM) monotherapy
Study: 23543447
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (LAM + ADV)
Study: 15756221
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) plus 70% lactulose (1 mL/kg/day)
Study: 15756221
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 70% lactulose (1 mL/kg/day)
Study: 8859237
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg bolus followed by saline infusion)
Study: 8859237
Drug: Propofol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.0 mg/kg bolus followed by 65 micrograms/kg/min infusion)
Study: 8396100
Drug: Amoxycillin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (30 mg/kg/day for 10 days in three divided doses; children > 20 kg received 250 mg tid daily)
Study: 3523741
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg X 2)
Study: 28795342
Drug: Cholecalciferol therapy
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol therapy (50,000 IU once a week for 12 weeks)
Study: 16164121
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 100 mg/day
Study: 12078940
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg + Amlodipine 5 mg (BZ+AM)
Study: 12078940
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + Hydrochlorothiazide 25 mg (CP+HT)
Study: 11008323
Drug: Glutathione (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione (5 g immediately before cisplatin)
Study: 11008323
Drug: Control (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2000 ml electrolyte infusion before and 2000 ml normal saline after cisplatin)
Study: 8536820
Drug: Voglibose 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 0.5 mg
Study: 8536820
Drug: Voglibose 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 1.0 mg
Study: 8536820
Drug: Voglibose 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 1.0 mg (3 times daily for 7 days)
Study: 8536820
Drug: Voglibose 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 2.0 mg
Study: 8536820
Drug: Voglibose 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose 5.0 mg
Study: 2621331
Drug: HCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG injection for ovulation induction
Study: 859943
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of INH 400 mg, rifampicin 450-600 mg, and myambutol 25 mg/kg for the first two months followed by 15 mg/kg
Study: 859943
Drug: Intermittent application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent application three times weekly of INH 600 mg, rifampicin 750 mg, and myambutol 30 mg/kg for the first two months followed by 20 mg/kg
Study: 859943
Drug: Intermittent application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent application twice weekly of INH 800 mg, rifampicin 900 mg, and myambutol 50 mg/kg for the first two months followed by 30 mg/kg
Study: 859943
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated by daily application of Str one gram for 6-8 months, INH 5-10 mg/kg and PAS 12-15 g daily
Study: 859943
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (A, B1, B2) compared to classical mode of treatment
Study: 19320276
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole capsule
Study: 10952406
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl plaster
Study: 10952406
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release morphine tablets
Study: 12603640
Drug: rizatriptan 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: rizatriptan 10‐mg standard tablets
Study: 12603640
Drug: rizatriptan 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: rizatriptan 10‐mg orally disintegrating tablets
Study: 12603640
Drug: Oral usual
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral usual care medications
Study: 8697550
Drug: 2M2V (mivacurium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2M2V (mivacurium 0.15 mg.kg‐1 plus vecuronium 0.1 mg.kg‐1)
Study: 2662837
Drug: Fenoterol syrup
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol syrup
Study: 29551699
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IMT + FES
Study: 27089049
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with tegafur–uracil (UFT)
Study: 17319428
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 10 mg + 15 microg fentanyl
Study: 17319428
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 11 mg + 15 microg fentanyl
Study: 17319428
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 12 mg + 15 microg fentanyl
Study: 17319428
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 13 mg + 15 microg fentanyl
Study: 17319428
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 14 mg (no fentanyl)
Study: 15003297
Drug: Ultrasound-guided BTX-A
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Ultrasound-guided BTX-A injections (Group A, n=8)
Study: 15003297
Drug: Blind BTX-A
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Blind BTX-A injections (Group B, n=7)
Study: 26179482
Drug: Tofogliflozin 10
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 10 mg
Study: 26179482
Drug: Tofogliflozin 40
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 40 mg
Study: 26179482
Drug: Tofogliflozin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofogliflozin (all doses)
Study: 21595861
Drug: Silicone oil
Normalized name: SILICONE OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone oil injection
Study: 21595861
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (BSS) injection
Study: 14671164
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg GH/m(2).d
Study: 14671164
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg GH/m(2).d
Study: 14671164
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg GH/m(2).d and 2 mg GH/m(2).d
Study: 1643677
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia (4 ml 0.5% isobaric bupivacaine)
Study: 1643677
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia (15 ml of 0.5% bupivacaine)
Study: 6375709
Drug: glaucine 30
Normalized name: glaucine
Approvals — FDA: no, EMA: no, PMDA: no
Description: glaucine 30 mg
Study: 6375709
Drug: dextromethorphan 30
Normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextromethorphan 30 mg
Study: 22924353
Drug: Oxalic acid-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxalic acid-based preparation
Study: 8539008
Drug: Objects presented
Normalized name: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
DrugBank: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine (DB15813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objects presented in the same category (sequential and simultaneous trials)
Study: 8539008
Drug: Objects presented
Normalized name: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
DrugBank: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine (DB15813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Objects presented in mixed categories (sequential and simultaneous trials)
Study: 8539008
Drug: Sequential presentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential presentation of objects
Study: 2379297
Drug: Rheum palmatum
Normalized name: RHEUM PALMATUM ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheum palmatum L
Study: 29932230
Drug: 200‐mg selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mg selenium yeast tablets
Study: 23063567
Drug: Intravenous silibinin
Normalized name: Silibinin
DrugBank: Silibinin (DB09298)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous silibinin (SIL)
Study: 18375894
Drug: MA 20
Normalized name: LENVIMA 20mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 20 mg
Study: 18375894
Drug: MA 40
Normalized name: Colace Micro-Enema 40 MG/ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 40 mg
Study: 10895743
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine (up to 300 mg)
Study: 1442579
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg once daily
Study: 31309775
Drug: IV ILO
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ILO once monthly
Study: 31309775
Drug: Not requiring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not requiring therapy with IV ILO
Study: 30249366
Drug: Gemigliptin 50
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin 50 mg once a day
Study: 30249366
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg BID
Study: 30249366
Drug: Gemigliptin +
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin + Metformin
Study: 25234012
Drug: Part-time patching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part-time patching for 3 hours daily for 5 months
Study: 25234012
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no treatment for 6 months)
Study: 20230254
Drug: Antofloxacin hydrochloride
Normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antofloxacin hydrochloride 200 mg
Study: 20230254
Drug: Antofloxacin hydrochloride
Normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antofloxacin hydrochloride 300 mg
Study: 20230254
Drug: Antofloxacin hydrochloride
Normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antofloxacin hydrochloride 400 mg
Study: 17266089
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention (EI) with intraarticular methylprednisolone injections
Study: 17266089
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (CT) with nonsteroidal antiinflammatory drugs
Study: 17266089
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (CT) with sulfasalazine
Study: 31518174
Drug: TAM +
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAM + OFS (5 years of Tamoxifen with 2 years of ovarian function suppression using monthly goserelin administration)
Study: 28698350
Drug: nanocurcumin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: nanocurcumin (40 mg capsules, 2 per day for 3 months)
Study: 28698350
Drug: placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (40 mg capsules, 2 per day for 3 months)
Study: 20368202
Drug: Glyburide plus
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide plus muraglitazar 2.5 mg
Study: 20368202
Drug: Glyburide plus
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide plus muraglitazar 5 mg
Study: 20368202
Drug: Glyburide plus
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide plus muraglitazar (both doses)
Study: 15367726
Drug: Oxcarbazepine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (1200 mg)
Study: 29351799
Drug: MedDiet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedDiet plus extravirgin OO, 20-30 g/day
Study: 17851756
Drug: Decongestive therapy
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestive therapy
Study: 7938858
Drug: Caudal puncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal puncture and anesthesia with 2.5 mg/kg bupivacaine 1:200,000
Study: 7938858
Drug: Lumbar puncture
Normalized name: Lumbar Puncture 18g 3.5"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar puncture at L4‐L5 and 1.25 mg/kg of bupivacaine
Study: 7938858
Drug: Epidural catheter
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural catheter in the caudal space up to L4‐L5 and 1.25 mg/kg of bupivacaine administered through the catheter
Study: 2836324
Drug: Imuthiol (Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imuthiol (Na diethyldithiocarbamate) adjuvant therapy
Study: 28353023
Drug: GUM Hydral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GUM Hydral mouthwash plus gel